Article
Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
Journal of virology - 9 Sept 2021
Ferrari Mathieu, Mekkaoui Leila, Ilca F Tudor, Akbar Zulaikha, Bughda Reyisa, Lamb Katarina, Ward Katarzyna, Parekh Farhaan, Karattil Rajeev, Allen Christopher, Wu Philip, Baldan Vania, Mattiuzzo Giada, Bentley Emma M, Takeuchi Yasuhiro, Sillibourne James, Datta Preeta, Kinna Alexander, Pule Martin, Onuoha Shimobi C
Abstract excerpt
The human angiotensin-converting enzyme 2 acts as the host cell receptor for SARS-CoV-2 and the other members of the Coronaviridae family SARS-CoV-1 and HCoV-NL63. Here, we report the biophysical properties of the SARS-CoV-2 spike variants D614G, B.1.1.7, B.1.351, and P.1 with affinities to the ACE2 receptor and infectivity capacity, revealing weaknesses in the developed neutralizing antibody approaches....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.